KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Income from Non-Controlling Interests (2016 - 2019)

CRISPR Therapeutics AG (CRSP) has disclosed Income from Non-Controlling Interests for 5 consecutive years, with $14.2 million as the latest value for Q1 2019.

  • Quarterly Income from Non-Controlling Interests rose 13.6% to $14.2 million in Q1 2019 from the year-ago period, while the trailing twelve-month figure was $54.4 million through Mar 2019, up 25.93% year-over-year, with the annual reading at $52.5 million for FY2018, 45.03% up from the prior year.
  • Income from Non-Controlling Interests hit $14.2 million in Q1 2019 for CRISPR Therapeutics AG, up from $14.1 million in the prior quarter.
  • In the past five years, Income from Non-Controlling Interests ranged from a high of $14.2 million in Q1 2019 to a low of -$16000.0 in Q4 2015.
  • Historically, Income from Non-Controlling Interests has averaged $6.9 million across 5 years, with a median of $9.0 million in 2017.
  • Biggest five-year swings in Income from Non-Controlling Interests: plummeted 1300.0% in 2016 and later surged 1150100.0% in 2017.
  • Year by year, Income from Non-Controlling Interests stood at -$16000.0 in 2015, then soared by 93.75% to -$1000.0 in 2016, then soared by 1150100.0% to $11.5 million in 2017, then grew by 22.61% to $14.1 million in 2018, then rose by 0.71% to $14.2 million in 2019.
  • Business Quant data shows Income from Non-Controlling Interests for CRSP at $14.2 million in Q1 2019, $14.1 million in Q4 2018, and $12.6 million in Q3 2018.